clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
Company profile
Ticker
AVRO
Exchange
Website
CEO
Geoff MacKay
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AvroBio, Inc.
SEC CIK
Corporate docs
Subsidiaries
AVROBIO Australia Pty Ltd • AVROBIO Securities Corporation ...
AVRO stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
14 Mar 24
S-4
Registration of securities issued in business combination transactions
13 Feb 24
425
Business combination disclosure
30 Jan 24
425
Business combination disclosure
30 Jan 24
8-K
Regulation FD Disclosure
30 Jan 24
425
Business combination disclosure
30 Jan 24
8-K
AVROBIO and Tectonic Therapeutic Announce Merger
30 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
RW
Registration withdrawal request
3 Nov 23
Latest ownership filings
SC 13G
Newtyn Management, LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
GMT CAPITAL CORP
13 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
Azadeh Golipour
5 Feb 24
4
Essra Ridha
5 Feb 24
4
Erik Ostrowski
5 Feb 24
4
Steven Avruch
5 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
24 Jan 24
SC 13G
BML Investment Partners, L.P.
24 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 106.53 mm | 106.53 mm | 106.53 mm | 106.53 mm | 106.53 mm | 106.53 mm |
Cash burn (monthly) | 6.28 mm | 827.92 k | 7.64 mm | 450.25 k | 6.74 mm | 6.57 mm |
Cash used (since last report) | 37.41 mm | 4.93 mm | 45.52 mm | 2.68 mm | 40.14 mm | 39.12 mm |
Cash remaining | 69.12 mm | 101.60 mm | 61.01 mm | 103.84 mm | 66.39 mm | 67.41 mm |
Runway (months of cash) | 11.0 | 122.7 | 8.0 | 230.6 | 9.8 | 10.3 |
Institutional ownership, Q2 2023
66.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 8 |
Closed positions | 13 |
Increased positions | 7 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 16.40 bn |
Total shares | 30.03 mm |
Total puts | 0.00 |
Total calls | 7.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Atlas Venture Life Science Advisors | 4.54 mm | $4.31 bn |
Clarus Lifesciences III | 2.96 mm | $49.53 mm |
Farallon Capital Partners | 2.86 mm | $4.84 mm |
Tang Capital Partners | 2.71 mm | $3.19 mm |
Tang Capital Management | 2.71 mm | $2.57 bn |
GMT Capital | 2.41 mm | $2.29 bn |
SVLSF Vi | 1.93 mm | $26.45 mm |
Acadian Asset Management | 1.77 mm | $1.68 mm |
Vanguard | 1.18 mm | $1.12 bn |
MS Morgan Stanley | 1.05 mm | $996.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Feb 24 | Steven Avruch | Common Stock | Payment of exercise | Dispose F | No | No | 1.202 | 10,812 | 13.00 k | 22,022 |
5 Feb 24 | Erik Ostrowski | Common Stock | Payment of exercise | Dispose F | No | No | 1.202 | 13,099 | 15.74 k | 29,285 |
5 Feb 24 | Essra Ridha | Common Stock | Payment of exercise | Dispose F | No | No | 1.2006 | 16,953 | 20.35 k | 15,881 |
5 Feb 24 | Azadeh Golipour | Common Stock | Payment of exercise | Dispose F | No | No | 1.2016 | 12,232 | 14.70 k | 55,872 |
1 Feb 24 | Steven Avruch | Common Stock | Option exercise | Acquire M | No | No | 0 | 32,834 | 0.00 | 32,834 |
1 Feb 24 | Steven Avruch | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 32,834 | 0.00 | 98,499 |
1 Feb 24 | Erik Ostrowski | Common Stock | Option exercise | Acquire M | No | No | 0 | 40,084 | 0.00 | 42,384 |
1 Feb 24 | Erik Ostrowski | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 40,084 | 0.00 | 120,249 |
1 Feb 24 | Essra Ridha | Common Stock | Option exercise | Acquire M | No | No | 0 | 32,834 | 0.00 | 32,834 |
1 Feb 24 | Essra Ridha | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 32,834 | 0.00 | 98,499 |
Press releases
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure
26 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, KAMN, AVRO
2 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
28 Feb 24
Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm
27 Feb 24
Tectonic Therapeutic Announces Participation at Investor Conferences in March
27 Feb 24